PJB-2024-153
ASSESSING TECOMA STANS COMPOUNDS AS GLP-1 AGONISTS AND INHIBITORS OF ALPHA-GLUCOSIDASE/ALPHA-AMYLASE
Hatice AKKAYA
Abstract
The identification of bioactive metabolites in Tecoma stans unveils its biological benefits and traditional uses, particularly in the context of diabetes mellitus. To identify key compounds, we conducted ADME-Tox and drug similarity tests to assess potential drug candidates in biological systems and evaluate toxicity risks. Ligands selected from the ADME assay underwent in silico molecular docking studies using Autodock Vina in Chimera 1.16 against the GLP-1 receptor, pivotal in insulin sensitivity, blood sugar regulation, and energy metabolism control. From the ADME test results, 26 secondary metabolites were identified as ligands. Among these, luteolin flavonoid stood out as the most active ligand, with a docking score of -6 kcal/mol and a binding energy of -74.76 kcal/mol. With active compounds such as luteolin found in Tecoma stans, there is potential to treat hyperglycemia by inhibiting α-glucosidase and α-amylase, suggesting an effective role in addressing subsequent diabetic complications.
Key words: Diabetes mellitus, hyperglycemia, in silico, Tecoma stans, α-amylase, α-glucosidase
To Cite this article:
Download
